Free Trial
NASDAQ:CAPR

Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Capricor Therapeutics logo
$17.63 -1.29 (-6.82%)
(As of 11:30 AM ET)

About Capricor Therapeutics Stock (NASDAQ:CAPR)

Key Stats

Today's Range
$17.02
$19.83
50-Day Range
$4.18
$21.99
52-Week Range
$2.90
$23.40
Volume
1.41 million shs
Average Volume
1.15 million shs
Market Capitalization
$801.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.50
Consensus Rating
Buy

Company Overview

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Capricor Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

CAPR MarketRank™: 

Capricor Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 266th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Capricor Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Capricor Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.22) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Capricor Therapeutics is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Capricor Therapeutics is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Capricor Therapeutics has a P/B Ratio of 11.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.61% of the outstanding shares of Capricor Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Capricor Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Capricor Therapeutics has recently decreased by 14.56%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Capricor Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Capricor Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.61% of the outstanding shares of Capricor Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Capricor Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Capricor Therapeutics has recently decreased by 14.56%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Capricor Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Capricor Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 9 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Capricor Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,999,998.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

  • Read more about Capricor Therapeutics' insider trading history.
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

Capricor Therapeutics granted ODD, ATMP status for deramiocel by EMA
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
What is HC Wainwright's Forecast for CAPR FY2024 Earnings?
Capricor Therapeutics initiated with a Buy at JonesResearch
See More Headlines

CAPR Stock Analysis - Frequently Asked Questions

Capricor Therapeutics' stock was trading at $4.89 at the beginning of 2024. Since then, CAPR stock has increased by 256.4% and is now trading at $17.43.
View the best growth stocks for 2024 here
.

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. Capricor Therapeutics had a negative net margin of 146.86% and a negative trailing twelve-month return on equity of 112.95%.

Top institutional investors of Capricor Therapeutics include Geode Capital Management LLC (1.41%), State Street Corp (1.13%), Ikarian Capital LLC and Point72 Asset Management L.P. (0.55%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat.
View institutional ownership trends
.

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/08/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CAPR
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.50
High Stock Price Target
$77.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+86.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-22,290,000.00
Net Margins
-146.86%
Pretax Margin
-146.86%

Debt

Sales & Book Value

Annual Sales
$25.18 million
Book Value
$1.50 per share

Miscellaneous

Free Float
40,014,000
Market Cap
$843.47 million
Optionable
Optionable
Beta
4.00

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:CAPR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners